Juanita Lopez
YOU?
Author Swipe
View article: Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology Open
Background The Experimental Cancer Medicine Centre (ECMC) Network supports UK-wide access to experimental cancer therapies, many of which require specific genomic alterations. This study aimed to develop expert consensus on essential genes…
View article: EXTH-59. Supporting development of novel brain tumour therapies through global collaboration: early insights from a novel therapeutics accelerator
EXTH-59. Supporting development of novel brain tumour therapies through global collaboration: early insights from a novel therapeutics accelerator Open
Researchers developing novel therapies for brain tumours must navigate numerous challenges, including selection of suitable preclinical studies, safety, trial design, evolving regulatory landscapes, and securing sustained funding. To addre…
View article: Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Open
Purpose: AXL, a receptor tyrosine kinase related to oncogenic processes, is aberrantly expressed in various cancers and associated with treatment resistance. Enapotamab vedotin (EnaV), a novel anti-AXL human IgG1 and monomethyl auristatin …
View article: Association Between Spanish-Language Patient Navigation and Adherence to Multi-Target Stool DNA Testing Among Spanish-Speaking Patients at Sanitas Medical Center
Association Between Spanish-Language Patient Navigation and Adherence to Multi-Target Stool DNA Testing Among Spanish-Speaking Patients at Sanitas Medical Center Open
Colorectal cancer (CRC) screening rates remain low among Spanish-speaking populations, in part due to language barriers. This study examined the association between Spanish-language patient navigation on adherence to multi-target stool DNA…
View article: AN INTERNATIONAL NOVEL THERAPEUTICS ACCELERATOR FOR BRAIN TUMOURS: EARLY IMPACT AND LESSONS LEARNED
AN INTERNATIONAL NOVEL THERAPEUTICS ACCELERATOR FOR BRAIN TUMOURS: EARLY IMPACT AND LESSONS LEARNED Open
AIMS Developing a translational programme for brain tumours involves navigating numerous challenges, including robustness of preclinical studies, safety, clinical trial design, understanding and addressing regulatory require- ments, and fu…
View article: Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort Open
Background Patients with recurrent glioblastoma (GBM) have a poor prognosis and limited treatment options. The authors report the efficacy and safety of lenvatinib plus pembrolizumab in participants with recurrent GBM enrolled in the phase…
View article: Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial Open
View article: A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma
A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma Open
View article: Adherence to Repeat Screening Completion for Colorectal Cancer Using the Multi-Target Stool DNA Test: Real-World Analysis of Patients from Federally Qualified Health Centers
Adherence to Repeat Screening Completion for Colorectal Cancer Using the Multi-Target Stool DNA Test: Real-World Analysis of Patients from Federally Qualified Health Centers Open
Introduction/Objectives: This real-world study examined adherence to repeat mt-sDNA among patients from federally qualified health centers (FQHCs) across the US and among different payer types. Methods: Data from Exact Sciences Laboratorie…
View article: Supplementary Table 1 from MANIFEST: Multiomic Platform for Cancer Immunotherapy
Supplementary Table 1 from MANIFEST: Multiomic Platform for Cancer Immunotherapy Open
Notable large-scale immuno-oncology consortia formed in the recent era.
View article: Impact of Spanish Language Outreach on Multi-Target Stool DNA Test Adherence in a Federally Qualified Health Center in the United States
Impact of Spanish Language Outreach on Multi-Target Stool DNA Test Adherence in a Federally Qualified Health Center in the United States Open
Introduction The objective of the current study was to examine the impact of Spanish-language patient outreach and navigation services on adherence to initial colorectal cancer (CRC) screening with multitarget stool DNA (mt-sDNA) testing i…
View article: Supplementary Table 1 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Table 1 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Table 1. Representativeness of Study Participants.
View article: Supplementary Table 6 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Table 6 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Table 6. Summary of AFM24 Serum Pharmacokinetic Parameters Following AFM24 IV Administration on Cycle 1 Day 22.
View article: Supplementary Figure 6 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Figure 6 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Figure 6. Clustering of cells shows a decrease of NK cells upon AFM24 treatment suggesting migration of NK cells to the tumor site.
View article: Supplementary Table 5 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Table 5 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Table 5. Summary of AFM24 Serum Pharmacokinetic Parameters Following AFM24 IV Administration on Cycle 1 Day 1.
View article: Supplementary Table 4 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Table 4 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Table 4. Overview of TEAEs per cohort.
View article: Supplementary Table 2 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Table 2 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Table 2. Definition of Dose Limiting Toxicities.
View article: Supplementary Methods 1 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Methods 1 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Methods 1. Inclusion criteria, Exclusion criteria, and Extended methods and data analysis.
View article: Supplementary Figure 3 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Figure 3 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Figure 3. Relationship between AFM24 concentrations and CD16A receptor occupancy on NK cells.
View article: Supplementary Table 7 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Table 7 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Table 7. Approximated apparent half-life of AFM24.
View article: Supplementary Table 3 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Table 3 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Table 3. Research Resource Identifiers (RRIDs).
View article: Supplementary Figure 4 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Figure 4 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Figure 4. Tumor EGFR expression was maintained during AFM24 treatment.
View article: Supplementary Figure 1 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Figure 1 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Figure 1. Number of patients with infusion-related reactions on each visit.
View article: Supplementary Figure 2 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Figure 2 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Figure 2. Box and whisker plots of AFM24 dose-normalized Cmax and dose normalized AUC0–168 following IV AFM24 administration on Cycle 1 Day 22.
View article: Supplementary Figure 5 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Figure 5 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Figure 5. Analysis of tissue biopsies indicates an increase of NK and T cell functions in the tumor upon AFM24 treatment.
View article: Supplementary Figure 6 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Figure 6 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Figure 6. Clustering of cells shows a decrease of NK cells upon AFM24 treatment suggesting migration of NK cells to the tumor site.
View article: Supplementary Figure 3 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Figure 3 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Figure 3. Relationship between AFM24 concentrations and CD16A receptor occupancy on NK cells.
View article: Supplementary Figure 2 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Figure 2 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Figure 2. Box and whisker plots of AFM24 dose-normalized Cmax and dose normalized AUC0–168 following IV AFM24 administration on Cycle 1 Day 22.
View article: Supplementary Table 5 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Table 5 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Table 5. Summary of AFM24 Serum Pharmacokinetic Parameters Following AFM24 IV Administration on Cycle 1 Day 1.
View article: Supplementary Figure 5 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors
Supplementary Figure 5 from First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors Open
Supplementary Figure 5. Analysis of tissue biopsies indicates an increase of NK and T cell functions in the tumor upon AFM24 treatment.